Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4731-4738

  Li, Guan Wu ^a   Xu, Zheng ^b   Chang, Shi Xin ^a   Zhou, Lei ^a   Wang, Xiao Yan ^a   Nian, Hua ^a   Shi, Xiao ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Xinzhuang Community Health Service Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADIPOCYTE; ADIPOGENESIS; ANIMAL; BODY WEIGHT; BONE DENSITY; BONE MARROW; BONE REMODELING; DRUG EFFECTS; FEMALE; LONGITUDINAL STUDY; OBESITY; OVARIECTOMY; RANDOMIZATION; SPRAGUE DAWLEY RAT; UTERUS;

ADIPOCYTES; ADIPOGENESIS; ADIPOSITY; ANIMALS; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BONE REMODELING; DIPHOSPHONATES; FEMALE; IMIDAZOLES; LONGITUDINAL STUDIES; OVARIECTOMY; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; UTERUS;

EID: 84914141371     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1359     Document Type: Article

References (34)

1. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13-20.
2. Basso FG, Silveira Turrioni AP, Hebling J, de Souza Costa CA. Zoledronic acid inhibits human osteoblast activities. Gerontology. 2013;59:534-541.
3. Koch FP, Merkel C, Al-Nawas B, et al. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner - a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. 2011;39:562-569.
4. Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol. 2009;54:851-856.
5. Pozzi S, Vallet S, Mukherjee S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009;15:5829-5839.
6. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2009;106:109-118.
7. Duque G, Li W, Vidal C, Bermeo S, Rivas D, Henderson J. Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice. J Bone Miner Res. 2013;28:639-648.
8. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18:456-462.
9. Bolan PJ, Arentsen L, Sueblinvong T, et al. Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. J Magn Reson Imaging. 2013;38:1578-1584.
10. Fazeli PK, Bredella MA, Freedman L, et al. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res. 2012;27:1864-1871.
11. Li GW, Chang SX, Fan JZ, Tian YN, Xu Z, He YM. Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy. Bone. 2013;52:668-675.
12. Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res. 2013;28:1721-1728.
13. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669-2680.
14. Brouwers JE, van Rietbergen B, Bouxsein ML. Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats. Calcif Tissue Int. 2008;83:186-191.
15. Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B, Huiskes R. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int. 2008;82:202-211.
16. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res. 2008;23:544-551.
17. Govindarajan P, Khassawna T, Kampschulte M, et al. Implications of combined ovariectomy and glucocorticoid (dexamethasone) treatment on mineral, microarchitectural, biomechanical and matrix properties of rat bone. Int J Exp Pathol. 2013;94:387-398.
18. Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL, Khosla S. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int. 2008;19:1323-1330.
19. Khajuria DK, Razdan R, Mahapatra DR. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats. J Orthop Sci. 2014;19:646-656.
20. Shin YH, Cho DC, Yu SH, Kim KT, Cho HJ, Sung JK. Histomorphometric analysis of the spine and femur in ovariectomized rats using micro-computed tomographic scan. J Korean Neurosurg Soc. 2012;52:1-6.
21. Glatt M, Pataki A, Evans GP, Hornby SB, Green JR. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int. 2004;15:707-715.
22. Patntirapong S, Singhatanadgit W, Chanruangvanit C, Lavanrattanakul K, Satravaha Y. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition. J Oral Pathol Med. 2012;41:713-720.
23. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 2008;82:191-201.
24. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25:4105-4115.
25. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res. 2000;302:353-363.
26. Li GW, Tang GY, Liu Y, Tang RB, Peng YF, Li W. MRspectroscopy and micro-CT in evaluation of osteoporosis model in rabbits: comparison with histopathology. Eur Radiol. 2012;22:923-929.
27. Lecka-Czernik B. Marrow fat metabolism is linked to the systemic energy metabolism. Bone. 2012;50:534-539.
28. Duque G, Li W, Adams M, Xu S, Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int. 2011;22:1547-1553.
29. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res. 2007;22:1603-1611.
30. Casado-Díaz A, Santiago-Mora R, Dorado G, Quesada-Gómez JM. Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. Arch Med Res. 2013;44:325-334.
31. Rickard DJ, Wang FL, Rodriguez-Rojas AM, et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone. 2006;39: 1361-1372.
32. Elbaz A, Wu X, Rivas D, Gimble JM, Duque G. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010;14:982-991.
33. Gunaratnam K, Vidal C, Gimble JM, Duque G. Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology. 2014;155:108-116.
34. Payne MW, Uhthoff HK, Trudel G. Anemia of immobility: caused by adipocyte accumulation in bone marrow. Med Hypotheses. 2007;69:778-786.